Effect of Cornus mas L. fruit extract on lipid accumulation product and cardiovascular indices in patients with non-alcoholic fatty liver disease: A double-blind randomized controlled trial
| Autor: | Mohsen Akhondi-Meybodi, Zohreh Sadat Sangsefidi, Mahdieh Hosseinzadeh, Abbas Ali Sangouni, Faezeh Yarhosseini, Farzan Madadizadeh, Ali Mohammad Ranjbar, Hassan Mozaffari-Khosravi |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Endocrinology Diabetes and Metabolism Iran Placebo Gastroenterology law.invention Insulin resistance Cornus Randomized controlled trial law Non-alcoholic Fatty Liver Disease Internal medicine Medicine Humans Nutrition and Dietetics business.industry Plant Extracts Fatty liver medicine.disease Obesity Clinical trial Fruit business Lipid Accumulation Product Dyslipidemia |
| Zdroj: | Clinical nutrition ESPEN. 47 |
| ISSN: | 2405-4577 |
| Popis: | Summary Background & Aims Non-alcoholic fatty liver disease (NAFLD) is associated with high risk of cardiovascular diseases. The experimental studies have suggested that Cornus mas L. (cornelian cherry) fruit can improve cardiovascular risk factors such as obesity, insulin resistance and dyslipidemia. We designed a study to investigate the effect of cornelian cherry fruit extract on cardiovascular outcomes in patients with NAFLD. Methods We conducted a double-blind, randomized controlled trial. Fifty patients with NAFLD were randomly assigned into the treatment and the control groups. The treatment group received 20 cc/d cornelian cherry fruit extract as liquid form and the control group received 20 cc/d placebo for 12 weeks. The primary outcomes included lipid accumulation product (LAP), atherogenic index of plasma (AIP), Castelli risk index I (CRI-I), CRI-II and atherogenic coefficient (AC). Results At the baseline, there was no significant difference between two groups in values of LAP, AIP, CRI-I, CRI-II and AC. After the intervention, no significant change was found in the treatment group compared to the control group in LAP (-0.64 (-6.25 to 8.29) vs. 0.0 (-8.66 to 19.01); P=0.91), AIP (0.0 ± 0.08 vs. 0.0 ± 0.1; P=0.84), CRI-I (-0.18 ± 0.63 vs. -0.31 ± 0.49; P=0.42), CRI-II (-0.23 ± 0.56 vs. -0.15 ± 0.32; P=0.52) and AC (-0.18 ± 0.63 vs. -0.31 ± 0.49; P=0.42). Conclusion Cornelian cherry fruit extract has no effect on cardiovascular outcomes. Further studies with longer intervention durations are needed. Trial registration Registered on 30 September 2018 at Iranian Registry of Clinical Trials (IRCT20180419039359N1). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect